In the landscape of modern mental health, the prevailing "disease model" has long dictated that chronic conditions like schizophrenia and bipolar disorder require lifelong management through a rotating cocktail of antipsychotics and mood stabilizers. However, a burgeoning movement known as "metabolic psychiatry" is beginning to challenge this orthodoxy. At the heart of this shift is an old tool repurposed for a new frontier: the ketogenic diet.
While the diet has been used for over a century to treat pediatric epilepsy, its application in psychiatry is now being framed not just as a supportive measure, but as a potentially transformative therapy that could lead to clinical remission and, in some cases, a medication-free future. Leading this charge is the Accord clinic in Arlington, Massachusetts—the first residential facility in the United States dedicated to pairing ketogenic therapy with supervised medication tapering.
Main Facts: A New Paradigm for Serious Mental Illness
The core premise of metabolic psychiatry, popularized by Harvard psychiatrist Chris Palmer in his 2022 book Brain Energy, posits that mental disorders are essentially metabolic disorders of the brain. The argument suggests that dysfunctional mitochondria—the organelles responsible for producing cellular energy—lead to the symptoms we categorize as psychiatric illness.
The Accord clinic, founded by psychiatrist Matt Bernstein, serves as a real-world laboratory for this theory. Unlike traditional psychiatric wards, Accord operates out of a two-story house, offering a domestic environment where patients learn to fuel their brains with ketones rather than glucose. The clinic’s approach is defined by a critical distinction:
- Adjunctive Therapy: Using the ketogenic diet as a "supplement" to existing drug regimens to mitigate side effects like weight gain and insulin resistance.
- Transformative Therapy: Using the diet as a primary restorative agent to improve physical and mental well-being to the point where psychiatric medications—which often worsen metabolic health—can be safely reduced or eliminated.
Accord is currently utilizing a $600,000 research grant to track long-term outcomes over 18 months, aiming to provide the evidence base necessary to move this treatment from the fringes of "lifestyle medicine" into the mainstream of psychiatric practice.
Chronology: From Pediatric Epilepsy to Metabolic Mind
The timeline of the ketogenic diet’s journey into psychiatry is marked by clinical observations that eventually coalesced into a formal movement.
- 1921: The ketogenic diet is developed at the Mayo Clinic as a treatment for epilepsy, mimicking the metabolic effects of fasting.
- 2017–2019: Dr. Chris Palmer publishes a series of case reports in peer-reviewed journals detailing "miraculous" recoveries. One 2017 report described two schizoaffective patients who achieved remission; one successfully withdrew from all medications.
- 2021: Matt Baszucki, son of Roblox founder David Baszucki, begins a ketogenic protocol under Dr. Palmer’s guidance after five years of "treatment-resistant" bipolar disorder involving 29 different medications. His recovery prompts the family to launch Metabolic Mind, a non-profit dedicated to funding research in metabolic psychiatry.
- 2022: The publication of Brain Energy provides a unified biological theory, linking mental health to mitochondrial function and metabolic health.
- July 2024: Dr. Matt Bernstein opens Accord in Arlington, MA, moving beyond outpatient advice to a fully immersive residential and day-program model.
Supporting Data: The Evidence Base for Metabolic Intervention
While anecdotal success stories are compelling, the medical community requires rigorous data. Current research suggests a strong correlation between metabolic intervention and symptom reduction.
The Comparison of Cohort Studies
Two recent studies provide a "natural experiment" on the impact of medication tapering alongside the diet:
- The French Study: Researchers treated 28 patients with severe mental illness in a hospital setting for two months. Crucially, 18 of these patients (64%) decreased their psychiatric medications during the trial. This cohort saw a 60% improvement in Clinical Global Impression (CGI-S) scores.
- The Stanford Study: A four-month study of 21 patients with bipolar or schizophrenia. In this trial, medication levels remained largely static (only 29% decreased use). This cohort saw a 31% improvement in CGI-S scores.
The data suggests that while the diet provides benefits as an add-on, the results are nearly twice as effective when paired with a reduction in the pharmacological burden.
Biological Mechanisms
The ketogenic diet (typically 70-80% fat, 15-20% protein, and 5-10% carbohydrates) forces the liver to produce ketones. According to Dr. Bernstein, this shift provides several neurological advantages:
- Alternative Fuel: Ketones bypass the insulin-resistant pathways that often starve the brain of energy in patients with metabolic dysfunction.
- Reduced Inflammation: Ketosis reduces oxidative stress and has systemic anti-inflammatory effects.
- Neuroplasticity: The diet increases levels of Brain-Derived Neurotrophic Factor (BDNF), a protein that supports the growth and connection of neurons.
- Mitochondrial Biogenesis: The diet stimulates the production of new, healthy mitochondria and the clearing of damaged ones (mitophagy).
Patient Narratives: Case Studies in Transformation
The human cost of the current psychiatric model is best illustrated by those who have lived through it. At Accord, the focus is on reclaiming lives that were previously defined by "polypharmacy"—the use of multiple powerful drugs.
The Case of Jack Grady
Jack Grady’s journey is what his mother, Mary Alice, calls "eight years of hell." After a manic break in college, Jack was cycled through a litany of drugs, including clozapine, the "last resort" antipsychotic. "He was a zombie," Mary Alice recalls. Jack describes his years on high-dose medication as a period of sedation and lost motivation, where voices in his head—hallucinations of celebrities and religious figures—remained constant despite the drugs.
After two months at Accord in early 2025, Jack began a slow taper of clozapine while maintaining strict ketosis. Two months after returning home, he experienced a breakthrough. "The voices are almost gone," Jack reported. He has since returned to work and built a music studio, regaining the "self-directed behavior" his family feared was gone forever.
The Case of Meredith Marks
Meredith Marks lived with a bipolar diagnosis for 27 years, undergoing 36 sessions of electroconvulsive therapy (ECT) and taking a regimen of seven different drugs. Despite holding a master’s degree in counseling, her life was punctuated by hospitalizations and severe weight gain.
Since joining Accord’s day program in March 2025, Meredith has lost significant weight and reduced her medication from seven drugs to five. "I felt ridiculously better within a month," she says. Beyond the physical changes, Meredith notes a shift in her authentic self: "I’m not just hiding from the world anymore. I’m an active member of my family."
Official Responses and Clinical Perspectives
Despite the successes at Accord, the movement faces significant structural and professional hurdles.
The "Liability" of Tapering
Dr. Bernstein acknowledges that many academic researchers are hesitant to include medication tapering in their study protocols. "The liability exposure is significant," Bernstein explains. Institutional Review Boards (IRBs) are often reluctant to approve studies that involve reducing antipsychotics, fearing a relapse in patients. Furthermore, tapering can "confound" data in short-term studies, making it difficult to isolate whether the diet or the drug reduction caused the improvement.
The Consensus Statement
In 2026, Palmer, Bernstein, and several other leaders in the field published a consensus statement in Frontiers in Nutrition. They formally recommended that "ketogenic metabolic therapy should be considered as adjunct therapy to first-line treatments."
Bernstein admits this "adjunct" label is partly political. "Metabolic psychiatry is fighting for acceptance within a specialty committed to the pharmacological model," he says. By framing it as an add-on, they avoid immediate attacks from the psychiatric establishment while building the "evidence base" necessary for more radical changes.
Implications: The Future of Metabolic Psychiatry
The work being done at Accord raises profound questions about the future of mental health care in the United States.
Sustainability and Support
A major criticism of the ketogenic diet is its difficulty. A 2026 UK study on treatment-resistant depression found that only 20% of participants could maintain the diet after active clinical support ended. Accord addresses this through "lifestyle medication"—a holistic approach that includes exercise, sunlight, and social connection. The clinic also utilizes health coaches like Donika Hristova, who provides online support to help clients transition back to their home environments.
Accessibility and Insurance
Currently, the "Accord model" is largely a luxury of the wealthy. With residential costs at $36,000 per month and no coverage from major insurance providers, the treatment remains inaccessible to the vast majority of the population. For metabolic psychiatry to achieve its "paradigm shift," it must move beyond boutique clinics and into standardized, insurance-reimbursable care.
The 18-Month Horizon
The ongoing research at Accord will be pivotal. If the 18-month data shows that a significant percentage of patients remain in remission with minimal or no medication, it will provide a powerful counter-narrative to the "chronic brain disease" model.
As society begins to view psychiatric drugs not just as cures, but as agents that can sometimes worsen metabolic health, the ketogenic diet stands as a bridge. It offers a path back to a restorative physical well-being that, for some, may finally chase away the shadows of psychiatric symptoms. In the words of Dr. Bernstein, "If you want the really good results, you have got to also taper. And when the brain finally has the right fuel, it starts coming back online."
